Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Fineline Cube Aug 6, 2026
Company Drug

Shandong Boan Biotech Submits BLA to Brazil’s ANVISA for Aflibercept Biosimilar BA9101, Expanding Global Ophthalmic Footprint

Fineline Cube Aug 6, 2026
Policy / Regulatory

NHSA Issues New Medical Service Pricing Policy to Enhance Public Welfare and Innovation

Fineline Cube Jul 20, 2022

The National Healthcare Security Administration (NHSA) has released a new notification on medical service pricing...

Company Medical Device

MicroPort CardioFlow Completes First Clinical Use of Dry Valve Transcatheter Mitral Valve System

Fineline Cube Jul 20, 2022

MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...

Company

WuXi Biologics to Build $1.4B CRDMO Hub in Singapore, Creating 1,500 Jobs

Fineline Cube Jul 20, 2022

China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...

Company Deals

Antengene and Celularity Partner on Bispecific Antibody and NK Cell Therapy Combo

Fineline Cube Jul 20, 2022

China-based Antengene Corporation Ltd (HKG: 6996) announced a preclinical partnership with U.S. firm Celularity Inc....

Drug

Kexing Pharmaceutical Launches Phase III Influenza Vaccine Study in Chile

Fineline Cube Jul 20, 2022

China-based Kexing Pharmaceutical (SHA: 688136) announced the start of a Phase III clinical trial in...

Drug

Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study

Fineline Cube Jul 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...

Company Drug

Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study

Fineline Cube Jul 20, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...

Company Drug

Eli Lilly’s Retevmo Wins Special Approval in China’s Lecheng Medical Pilot Zone

Fineline Cube Jul 20, 2022

Eli Lilly & Co. (NYSE: LLY) has secured special approval for its RET kinase inhibitor...

Company Deals

Attec Completes Pre-Series A Financing with Sequoia China Backing Protein Degradation Tech

Fineline Cube Jul 19, 2022

China-based biotech startup Attec has completed a pre-Series A financing round, with its protein degradation...

Company Drug

Innovent Biologics’ Mazdutide Meets Phase II Goals in Type 2 Diabetes Study

Fineline Cube Jul 19, 2022

China-based Innovent Biologics Inc. (HKG: 1801) announced that its Phase II study of mazdutide (IBI362/OXM3)...

Company Deals

Digital Precision Medicine Raises Hundreds of Millions in Series B Financing for Molecular Imaging Innovation

Fineline Cube Jul 19, 2022

China-based Digital Precision Medicine (DPM), a molecular imaging and fluorescence endoscopy manufacturer, has reportedly raised...

Company Drug

Sihuan Pharma’s Fourth-Gen Insulin Degludec NDA Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its New Drug Application (NDA)...

Company Drug

Sihuan Pharma’s Anaprazole Enters Phase II Study for Reflux Esophagitis

Fineline Cube Jul 19, 2022

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that its subsidiary Xuanzhu Biopharmaceutical Co.,...

Company R&D

Takeda Opens R&D Asia-Pacific Headquarters in Shanghai to Boost Drug Development

Fineline Cube Jul 19, 2022

Japan’s Takeda Pharmaceutical Co., Ltd has inaugurated its R&D Asia-Pacific headquarters in Pudong, Shanghai. The...

Company Deals

Tongling Bionic Raises Hundreds of Millions in Series B Financing for Cardiopulmonary Equipment Development

Fineline Cube Jul 19, 2022

Anhui Tongling Bionic Technology Co., Ltd, a Chinese developer of cardiopulmonary circulatory assist equipment, has...

Company Drug

Sesen Bio Terminates Vicineum Development After FDA Talks, Citing Phase III Costs

Fineline Cube Jul 19, 2022

Sesen Bio Inc. (NASDAQ: SESN) announced the termination of clinical development for Vicineum (VB4-845), its...

Company Medical Device

Huadong Medicine’s GFR Monitoring System Accepted by NMPA for Review

Fineline Cube Jul 19, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a glomerular...

Company Drug

Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis

Fineline Cube Jul 19, 2022

Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...

Company Drug

Humanwell Healthcare’s RFUS-144 Wins NMPA Approval for Pruritus Clinical Study

Fineline Cube Jul 19, 2022

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that its Category 1 drug RFUS-144...

Company Deals

Brii Biosciences Partners with Huarun Medicine to Commercialize COVID-19 Antibody Cocktail in China

Fineline Cube Jul 19, 2022

China-based Brii Biosciences Ltd (HKG: 2137) announced a partnership with Huarun Medicine Business Group International...

Posts pagination

1 … 686 687 688 … 704

Recent updates

  • Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline
  • Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook
  • Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults
  • Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China
  • Luye Pharma’s Novel VMAT2 Inhibitor LY03015 Completes US Bridging Trial with Enhanced Safety Profile in Caucasian Subjects
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Gilead Sciences Reports Q2 2026 Revenue of $7.8B, Driven by HIV Franchise and Trodelvy Growth Despite Cell Therapy Decline

Company

Astellas Reports Record Q1 FY2026 Revenue of ¥640.9B, Driven by Strategic Brands Growth and Raises Full-Year Outlook

Company Drug

Takeda Receives FDA Approval for ORZEYFUL (oveporexton), First Oral OX2R Agonist for Narcolepsy Type 1 in Adults

Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.